Drug Saftey Information

Baker, Danial E.
November 2007
Hospital Pharmacy;Nov2007, Vol. 42 Issue 11, p978
Academic Journal
The author expresses his opinion on drug safety in regards to the medical community and the U.S. Food and Drug Administration (FDA). He cites a study published in the "Archives of Internal Medicine" which found that the number of adverse drug events (ADEs) reported increased 2.6-fold. He notes the need for health care providers to keep informed with new reports and labeling changes related to drug safety. He also acknowledges the new FDA newsletter "Drug Safety Newsletter."


Related Articles

  • FDA warns of potential intestinal issues with olmesartan medoxomil.  // Cardiology Today;Aug2013, Vol. 16 Issue 8, p18 

    The article reports that the U.S. Food and Drug Administration (FDA) approved the labeling changes to drugs containing olmesartan medoxomil, issuing a warning on its potential for intestinal problems.

  • FDA adds boxed warning to propylthiouracil. Kalwaitis, Katie; Southall, Jennifer // Endocrine Today;May2010, Vol. 8 Issue 5, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has added a boxed warning to propylthiouracil to include risks of severe liver injury and acute liver failure.

  • Boxed Warnings and Other FDA Communication Tools. MARKS, NORMAN S.; WEISS, KAREN // American Family Physician;2/1/2010, Vol. 81 Issue 3, p259 

    The authors talk about various risk communication tools used by the U.S. Food and Drug Administration (FDA) to inform the public about risks associated with a prescription drug. They state that a boxed warning in the prescribing information is one of these tools. They mention the requirement...

  • Boxed warning now required for antiphychotics for elderly with dementia.  // Primary Care Reports;Aug2008 Pharmacology Watch, p1 

    This article reports on a policy issued by the U.S. Food and Drug Administration in 2008 requiring a boxed warning for conventional antipsychotics. The policy concerns with an increased risk of mortality in elderly patients treated for dementia-elated psychosis. The policy expands the warning on...

  • FDA to revise all PPI labels to warn about possible fracture risk.  // Formulary;Jun2010, Vol. 45 Issue 6, p188 

    The article discusses a decision by the U.S. Food and Drug Administration (FDA) to revise the warning labels for all prescription and over-the-counter (OTC) proton pump inhibitors (PPIs). Popular PPI's include omeprazole (Prilosec) and Lansoprazole (Prevacid). According to the FDA the PPI labels...

  • BUGGING OUT. Hutson, Matthew // Psychology Today;Sep/Oct2006, Vol. 39 Issue 5, p33 

    The article discusses the side effects of ritalin. The side effects reportedly appear in up to 5 percent of children, and many sufferers complain of bug or worm infestations. Children are having delusions that they see critters or even feel them under their skin. Ritalin act on dopamine in the...

  • Warning About Byetta and Pancreatitis.  // Diabetes Health;Feb/Mar2008, Vol. 17 Issue 1, p32 

    The article reports that the U.S. Food and Drug Administration (FDA) has received complaints of acute pancreatitis among patients with type 2 diabetes who have been administered with Byetta. Out of the 30 patients, 27 had one or more risk factors for acute pancreatitis, such as gallstones or...

  • DRUG SAFETY COMMUNICATIONS: PRINCIPLES, PRACTICE, AND EVALUATION. Eby, Michelle // AMWA Journal: American Medical Writers Association Journal;2012, Vol. 27 Issue 4, p160 

    The article focuses on the lecture titled "Drug Safety Communications: Principles, Practice, and Evaluation" given by doctor Laura Pincock during the special session of the U.S. Food and Drug Administration (FDA) at the American Medical Writers Association (AMWA) annual conference. It says that...

  • FDA requests warning for contrast agents used on MRI images.  // Healthcare Purchasing News;Jul2007, Vol. 31 Issue 7, p10 

    The article reports on the request made by the U.S. Food and Drug Administration (FDA) to drug manufacturers to include a new boxed warning on the label of all gadolinium-based contrast agents used to enhance the quality of magnetic resonance imaging (MRI). The warning would inform patients with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics